Noble Financial Starts Evoke Pharma (EVOK) at Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/5/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
Brean Capital Reiterates Buy After Evoke Pharma (EVOK) Extends Interest-Payment-Only Period
October 7, 2015 11:52 AM EDTBrean Capital reiterated a Buy rating and $13.00 price target on Evoke Pharma (NASDAQ: EVOK) after negotiating for its interest-payment-only period to be extended for another year. The deal reduces Evokes debt payments by $2.2 million in the next year by eliminating principal payments and... More
